Table 2.
Intervention group – Control group | Intervention group | Control group | |||||||
---|---|---|---|---|---|---|---|---|---|
Mean difference of change | (95% CI) | P | Mean change | (95% CI) | P | Mean change | (95% CI) | P | |
DAS28 | −0·06 | −0·34, 0·22 | 0·66 | 0·14 | −0·07, 0·34 | 0·19 | 0·20 | 0·00, 0·39 | 0·05 |
DAS28-CRP | 0·05 | −0·28, 0·19 | 0·70 | 0·14 | −0·03, 0·31 | 0·10 | 0·10 | −0·07, 0·26 | 0·24 |
ESR (mm/h) | −1·05 | −3·97, 1·86 | 0·47 | 1·09 | −0·40, 2·57 | 0·15 | 2·14 | −0·36, 4·64 | 0·09 |
CRP (mg/L) | −1·07 | −2·02, −0·12 | 0·03 | 0·13 | −0·10, 0·35 | 0·26 | 1·20 | 0·29, 2·10 | 0·01 |
Swollen joints (28) | 0·13 | −2·18, 0·61 | 0·60 | 0·13 | −0·27, 0·53 | 0·52 | 0·00 | −0·29, 0·29 | 1·00 |
Tender joints (28) | 0·33 | −0·47, 1·13 | 0·42 | 0·47 | −0·05, 0·99 | 0·08 | 0·14 | −0·47, 0·75 | 0·65 |
VAS Global health (mm)* | 4·29 | −2·58, 11·16 | 0·22 | 2·49 | −2·59, 7·56 | 0·33 | −1·80 | −6·57, 2·97 | 0·45 |
VAS Pain (mm)* | −0·24 | −7·89, 7·40 | 0·95 | 0·98 | −4·74, 6·69 | 0·73 | 1·22 | −4·02, 6·47 | 0·64 |
HAQ* | 0·02 | −0·10, 0·13 | 0·79 | 0·04 | −0·04, 0·12 | 0·34 | 0·02 | −0·05, 0·10 | 0·51 |
NRS Satisfaction* | 0·25 | −0·37, 0·88 | 0·43 | −0·19 | −0·57, 0·18 | 0·31 | −0·44 | −0·94, 0·06 | 0·09 |
NRS Confidence* | 0·20 | −0·29, 0·69 | 0·42 | 0·00 | −0·22, 0·22 | 1·00 | −0·20 | −0·63, 0·23 | 0·36 |
Independent sample t-test for comparison between and Paired t-test for comparison within the groups.
Also analysed by Mann–Whitney U test and Wilcoxon signed ranks test with non-significant (P > 0·05) results.
DAS, Diseases Activity Score (scale 0–10); ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Swollen and Tender joint (28 count); VAS, Visual Analogue Scales, VAS Global health (scale 0–100 best to worse), VAS Pain (scale 0–100 best to worse); HAQ, Health Assessment Questionnaire (0–3 best to worse); NRS, Numerical Rating Scale, NRS Satisfaction and NRS Confidence (0–10 worse to best).